Article Abstract

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?

Authors: Shigeru Tanzawa, Masashi Ishihara, Terunobu Haruyama, Ryosuke Ochiai, Takahiko Sakamoto, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki

Abstract

Currently, three strategies for primary treatment of advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations are being investigated: epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy, EGFR-TKI + vascular endothelial growth factor (VEGF) inhibitor combination, and EGFR-TKI + cytotoxic anticancer agent combination (Tables 1,2).

Article Options

Download Citation